Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 30, 2006
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates through two reportable segments: Healthcare Distribution (dental, medical, animal health, and international) and Technology (software and value-added services). It serves over 500,000 customers worldwide with operations in 17 countries outside North America.
Key Financial Metrics
| Metric | 2006 (in thousands) | 2005 (in thousands) |
|---|---|---|
| Net Sales | $5,153,097 | $4,635,929 |
| Gross Profit | $1,480,055 | $1,316,936 |
| Gross Margin | 28.7% | 28.4% |
| Operating Income | $304,897 | $263,138 |
| Net Income | $163,759 | $139,759 |
| Diluted EPS | $1.82 | $1.58 |
| Cash from Operating Activities | $235,317 | $254,776 |
| Total Debt | $499,370 | $524,626 |
| Working Capital | $834,760 | $860,295 |
| Cash and Cash Equivalents | $248,647 | $210,683 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.2% to $5.15 billion, driven by 10.6% local currency growth (5.2% organic, 5.4% acquisitions) and 0.6% foreign currency impact.
- Segment Performance:
- Dental: Sales up 12.7% to $2.14 billion.
- Medical: Sales up 8.8% to $1.52 billion, primarily due to acquisitions.
- International: Sales up 11.5% to $1.40 billion.
- Technology: Sales up 11.3% to $98.2 million.
- Profitability: Operating income rose 15.9% to $304.9 million. Net income increased 17.2% to $163.8 million.
- Discontinued Operations: The company sold its Hospital Supply Business in April 2006, resulting in a $19.4 million after-tax loss recorded in discontinued operations.
- Acquisitions: Significant acquisitions included the Darby Group (dental and medical) and NLS Animal Health, contributing to revenue growth and goodwill increases.
Guidance, Outlook, Risks, and Unusual Items
- Capital Allocation: The company expects to invest $45.0 million to $50.0 million in capital projects in 2007. It maintains a stock repurchase program with $71.2 million remaining as of year-end.
- Dividends: No cash dividends were declared in 2006; the company intends to retain earnings for expansion and debt reduction.
- Key Risks:
- Regulatory: Subject to extensive federal and state regulations regarding pharmaceutical distribution (e.g., Prescription Drug Marketing Act) and healthcare fraud.
- Competition: Highly competitive market with pressure from manufacturers selling directly and other distributors.
- Supply Chain: Dependence on third-party suppliers for substantially all products; risk of supply interruptions.
- Interest Rates: Exposure to variable interest rates on $210 million of senior notes via swap agreements.
- Unusual Items:
- Adoption of FAS 123(R) for stock-based compensation, resulting in a cumulative reduction of retained earnings of $44.2 million.
- Change in net investment hedging methodology resulted in a $2.0 million pre-tax gain and $2.8 million reduction in interest expense.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of the Darby Group and NLS Animal Health and the realization of projected synergies.
- Discontinued Operations Impact: Confirm the final settlement of transitional service obligations related to the Hospital Supply Business divestiture.
- Regulatory Compliance: Monitor ongoing litigation and regulatory changes regarding pharmaceutical pedigree requirements and healthcare fraud.
- Debt Structure: Review the terms of the $240 million convertible debt due 2034 and the impact of variable interest rates on the $210 million senior notes.
- Stock-Based Compensation: Assess the impact of FAS 123(R) adoption on future earnings and cash flow.